Incidence of Cholangiocarcinoma with or without Previous Resection of Liver for Hepatolithiasis

Joon Young Lee, Jae Seon Kim, Ji Mi Moon, Sang-ah Lim, Wonho Chung, Eun-Hye Lim, Beom Jae Lee, Jong-Jae Park, and Young-Tae Bak

Division of Gastroenterology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea

Background/Aims: To investigate the incidence of cholangiocarcinoma in patients with hepatolithiasis with or without previous resection of liver. Methods: From 2002 to 2009, we retrospectively reviewed 117 patients who were diagnosed and treated for hepatolithiasis in Korea University Guro Hospital. Among the 117 patients, 55 patients who were lost during follow-up were excluded, and 62 patients were eligible for analysis. The hepatic resection group (n=25) included patients who underwent left hemihepatectomy (n=2); left lateral segmentectomy (n=10); left lobectomy (n=9); right lobectomy (n=3); or wedge resection (n=1). The nonhepatic resection group (n=37) included transhepatic cholangiographic lithotomy and endoscopic retrograde cholangiopancreatography-treated patients. The mean follow-up period was 47 months. Results: The incidence of cholangiocarcinoma while patients were followed for hepatolithiasis was 12.9% (8/62) (hepatic resection group, three cases [12%] vs nonhepatic resection group, five cases [13.5%]; p=1.000). The mean follow-up period was 53 months (47±11 months) until the diagnosis of cholangiocarcinoma. Conclusions: There was no difference in the incidence of cholangiocarcinoma according to previous liver resections. Patients with hepatolithiasis should be carefully followed up for detection of cholangiocarcinoma even after a previous liver resection. (Gut Liver 2013;7:475-479)

Key Words: Hepatolithiasis; Cholangiocarcinoma; Liver resection

INTRODUCTION

Hepatolithiasis is common in East Asian countries where the incidence has been reported to be 20% to 30% of all patients undergoing surgery for gallstone disease.1,2 Even though hepatolithiasis is considered benign in nature, it frequently recurs and may lead to cirrhosis and liver failure.3-5 In 1942, Sane and Maccallum6 first reported an association between hepatolithiasis and cholangiocarcinoma, which was then confirmed by many investigators that the development rate of intrahepatic cholangiocarcinoma while patients were being treated and followed for intrahepatic ductal stones was 4% to 11%.6-9

However, accurate diagnosis of cholangiocarcinoma associated with hepatolithiasis is very difficult in preoperative imaging studies and even during operation, since the affected liver segment is often fibrotic and scarred. Furthermore, it was reported that cholangiocarcinoma with stones is associated with significantly poorer survival than cholangiocarcinoma alone.10

The exact mechanism of cholangiocarcinoma arising from hepatolithiasis is not definitely clear. However bile stasis, chronic bacterial infection, and mechanical irritation of bile duct resulting in the atypical epithelium may play a role in the development of cancerous lesions.11-13 Hepatic resection is an established treatment and is recommended for its ability to resolve recurrent stone formation, cholangitis and also biliary strictures.14-16 However, there is no definite evidence and data rather hepatic resection for intrahepatic stones may reduce the development of cholangiocarcinoma.

The aim of this study is to investigate the incidence and clinical characteristics of cholangiocarcinoma during the follow-up of hepatolithiasis with or without previous resection of liver segment or lobe.
MATERIALS AND METHODS

From January 2002 to May 2009, we retrospectively reviewed 117 patients who were diagnosed and treated for hepatolithiasis in Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. Among 117 patients, 52 patients who were lost during follow-up and three patients who had malignancy elsewhere including stomach and ovary were excluded. Sixty-two patients were eligible for analysis with a mean follow-up of 47±11 months (Fig. 1).

Of the 62 patients with hepatolithiasis, 25 underwent hepatic resection (hepatic resection group) and 37 were treated without hepatic resection (nonhepatic resection group). Among the hepatic resection group, 10 patients underwent left lateral segmentectomy, nine by left lobectomy, three by right lobectomy, two by left hemihpatectomy, and one by wedge resection. Among the nonhepatic resection group, 14 patients were treated by percutaneous transhepatic cholangioscopic lithotomy (PTCLS), 10 by endoscopic retrograde cholangiopancreatography (ERCP), three by cholecystectomy with common bile duct exploration, two by choledocojejunostomy, and eight patient underwent observation due to old age or patients request (Table 1).

We compared the two groups (hepatic resection group and nonhepatic resection group) with regard to clinical features such as: gender, age, location of the intrahepatic ductal stone, and tumor markers (carcinoembryonic antigen [CEA] and carbohydrate antigen [CA] 19-9). We retrospectively investigated the incidence and the location of cholangiocarcinoma in both groups during the follow-up period.

Statistical significance was tested by two sample t-test for continuous variables. Fisher’s exact test was used for categorical variables. Comparison of the cholangiocarcinoma development between the two groups was analyzed with Mann-Whitney U test. A value of p<0.05 was considered to be significant.

RESULTS

1. Patient characteristics

We compared the two groups with regard to the clinical characteristics. The results are summarized in Table 2. Mean age in hepatic resection group was significantly younger than the nonhepatic resection group but no significant difference in the gender and duration of follow-up period between the two groups. Aspartate aminotransferase, alanine aminotransfer, total bilirubin, and gamma-glutamyl transferase level was higher in the hepatic resection group but no significant difference in tumor markers (CEA and CA 19-9).

2. Incidence of cholangiocarcinoma in regard to the hepatic resection

During the follow-up period of 62 patients with hepatolithiasis, eight patients (12.9%) developed cholangiocarcinoma. Of the 25 patients in hepatic resection group, three (12.0%) developed cholangiocarcinoma and of 37 patients in nonhepatic resection group, five (13.5%) developed cholangiocarcinoma. There were no significant difference in developing cholangiocarcinoma between the two groups (p=1.000) (Fig. 2).

3. Clinical characteristics of the patients who developed cholangiocarcinoma

The mean follow-up period was 53 months (47±11 months) for eight patients who had developed cholangiocarcinoma until the diagnosis of hepatolithiasis. Three cases (case 1 to 3) developed cholangiocarcinoma in hepatic resection group. Case 1 underwent left lateral segmentectomy due to a left lobar ductal stone. After 109 months of follow-up duration, ductal stone had recurred and underwent left lobectomy. The final pathol-

---

Table 1. Methods of Treatment in the Liver Resection Group and the Non-Liver Resection Group

| Methods of treatment                                      | No. |
|-----------------------------------------------------------|-----|
| Liver resection group (n=25)                              |     |
| Lt. hemihpatectomy                                        | 2   |
| Lt. lateral segmentectomy                                 | 10  |
| Lt. lobectomy                                             | 9   |
| Rt. lobectomy                                             | 3   |
| Wedge resection                                           | 1   |
| Non-liver resection group (n=37)                          |     |
| Cholecystectomy with CBD explore                          | 3   |
| Choledocojejunostomy                                      | 2   |
| Transhepatic-cholangiographic lithotomy                   | 14  |
| Endoscopic retrograde cholangiopancreatography            | 10  |
| Observation*                                              | 8   |

Lt., left; Rt., right; CBD, common bile duct.
*Observation due to old age and patient requests.
ogy was cholangiocarcinoma. Case 2 had cholangiocarcinoma at right lobe 82 months after left lateral segmentectomy for bilateral ductal stones. Case 3 had cholangiocarcinoma arising from caudate lobe 8 months after left lobectomy suggesting a hidden malignancy at the time of operation (Table 3).

Five cases developed cholangiocarcinoma in nonhepatic resection group. Intrahepatic ductal stones were treated mainly through PTCLS and ERCP. As for five cases of nonhepatic resection group, cholangiocarcinoma occurred from the same place as the stone existed (Table 4). In cases 2, 3, and 5, the growth pattern of tumor was an intraductal type so the diagnosis was made through biopsy from choledochoscopy.

**DISCUSSION**

Risk factors for intrahepatic cholangiocarcinoma include intrahepatic ductal stones, cystic liver disease, Clonorchis sinensis, primary biliary cirrhosis, ulcerative colitis, and Carolis disease.\(^{17-21}\) Especially in Asia, intrahepatic ductal stone is one of the factors that have been highly associated with cholangiocarcinoma.\(^{22,23}\)

Since cholangiocarcinoma associated with stones has poorer prognosis than cholangiocarcinoma alone, early diagnosis is crucial. Current diagnostic modalities including tumor markers

---

**Table 2.** Comparisons of the Characteristics of the Liver Resection and Non-Liver Resection Groups

| Characteristic       | Liver resection group (n=25) | Non-liver resection group (n=37) | p-value |
|----------------------|------------------------------|----------------------------------|---------|
| Age, yr              | 56±16                        | 61±23                            | 0.008*  |
| Duration, mo         | 63±21                        | 36±18                            | 0.081*  |
| Sex, male:female     | 16:21                        | 5:20                             | 0.058†  |
| AST                  | 41±22                        | 14±65                            | 0.000*  |
| ALT                  | 51±27                        | 133±53                           | 0.021*  |
| Total bilirubin      | 1.74±1.19                    | 2.71±2.29                        | 0.060*  |
| ALP                  | 136±67                       | 184±82                           | 0.231*  |
| GGT                  | 138±72                       | 343±172                          | 0.004*  |
| CEA                  | 1.27±0.87                    | 1.86±1.21                        | 0.260*  |
| CA 19-9              | 99.21±69.30                  | 45.93±24.31                      | 0.401*  |

Data are presented as mean±SD.

AST, aspartate aminotransferase; ALT, alanine aminotransfere; ALP, alkaline phosphatase; GGT, gamma-glutamyl transferase; CEA, carcinoembryonic antigen; CA, carbohydrate antigen.

*Statistical significance was tested by the two sample t-test for continuous variables; † Fisher exact test for categorical variables.

**Table 3.** Clinical Characteristics of Cholangiocarcinoma with Previous Liver Resection

| Case | Age/Sex | Stone location | Cancer location | Liver resection for IHD stone | Follow-up before cancer diagnosis, mo | Morphology |
|------|---------|----------------|----------------|------------------------------|--------------------------------------|------------|
| 1    | 51/F    | Left           | Left           | Left lateral segmentectomy   | 109                                  | Intraductal |
| 2    | 56/F    | Both           | Right          | Left lateral segmentectomy   | 82                                   | Mass-forming |
| 3    | 47/F    | Left           | Caudate lobe   | Left lobectomy               | 8                                    | Mass-forming |

IHD, intrahepatic duct; F, female.

**Table 4.** Clinical Characteristics of Cholangiocarcinoma without Previous Liver Resection

| Case | Age/Sex | Stone location | Cancer location | Previous surgical procedure | Treatment of IHD stone | F/U before diagnosis, mo* | Morphology |
|------|---------|----------------|----------------|----------------------------|------------------------|--------------------------|------------|
| 1    | 56/F    | Right          | Right          | Cholecystectomy            | THCL                   | 110                      | Mass-forming |
| 2    | 71/F    | Left           | Right          | Cholecystectomy            | THCL                   | 68                       | Intraductal |
| 3    | 65/M    | Left           | Left           | Cholecystectomy            | ERCP                   | 13                       | Intraductal |
| 4    | 51/M    | Both           | Left           | -                          | ERCP                   | 13                       | Mass-forming |
| 5    | 66/M    | Left           | Left           | -                          | THCL                   | 21                       | Intraductal |

IHD, intrahepatic duct; F/U, follow-up; F, female; THCL, transhepatic cholangiographic lithotomy; M, male; ERCP, endoscopic retrograde cholangiopancreatography.

*Mean follow-up periods before the diagnosis of cholangiocarcinoma.
(CA 19-9 and CEA) and advanced imaging studies such as helical computed tomography (CT), magnetic resonance cholangiogram are widely used for early detection. Recent study reported a “helical CT criteria” which include the periductal soft tissue density, ductal wall thickening, ductal enhancement on portal venous phase being useful for the diagnosis. However, the accurate preoperative diagnosis of cholangiocarcinoma in association with hepatolithiasis remains difficult. Furthermore, unlike the mass forming type, intraductal type of cholangiocarcinoma is especially difficult to predict through conventional diagnostic tools whether an accompanying malignancy exists in patients with hepatolithiasis. Of the eight patients with coexisting cholangiocarcinoma in this study, four patients showed intraductal type of growth pattern with two patients diagnosed by cholangioscopy and one case diagnosed only through surgical resection.

Nonsurgical procedures such as percutaneous transhepatic cholangioscopic lithotripsy and peroral choangioscopic lithotripsy have been used to treat hepatolithiasis. Although these procedures markedly increase the stone clearance rate, the high rates of residual stones and of recurrence of stones have been serious problems, especially in patients with biliary strictures. Hepatic resection is the most definitive approach to treating hepatolithiasis and can remove both intrahepatic stones and the strictured bile duct responsible for stone formation. Thus, recent report suggests hepatic resection may offer another advantage in eliminating the risk of new development of cholangiocarcinoma in patients with hepatolithiasis. But in contrast, incidence of cholangiocarcinoma showed no significant difference among patients with hepatolithiasis with or without previous hepatic resection.

In this study, during the 53 months of mean follow-up period in patients with hepatolithiasis, eight patients (12.9%) developed cholangiocarcinoma. No significant difference was found in the development of cholangiocarcinoma among hepatic resection group and nonhepatic resection group (12.0% vs 13.5%, p=1.000). Furthermore, there were no difference between the two groups in clinical manifestation and laboratory data to predict the development of malignancy. Limitation of the study is that the study design is retrospective, cross sectional, and the number of patients enrolled was too small. However it is difficult to conclude rather hepatic resection definitely prevents the development of cholangiocarcinoma in patients with hepatolithiasis.

In conclusion, patients with hepatolithiasis should be carefully followed up for detection of cholangiocarcinoma even after previous resection of liver segment or lobe.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

REFERENCES

1. Nakayama F, Soloway RD, Nakama T, et al. Hepatolithiasis in East Asia. Retrospective study. Dig Dis Sci 1986;31:21-26.
2. Su CH, Lui WY, P’eng FK. Relative prevalence of gallstone diseases in Taiwan. A nationwide cooperative study. Dig Dis Sci 1992;37:764-768.
3. Chijiwa K, Yamashita H, Yoshida J, Kuroki S, Tanaka M. Current management and long-term prognosis of hepatolithiasis. Arch Surg 1995;130:194-197.
4. Jan YY, Chen MF, Wang CS, Jeng LB, Hwang TL, Chen SC. Surgical treatment of hepatolithiasis: long-term results. Surgery 1996;120:509-514.
5. Yeh YH, Huang MH, Yang JC, Mo LR, Lin J, Yueh SK. Percutaneous trans-hepatic choangioscopy and lithotripsy in the treatment of intrahepatic stones: a study with 5 year follow-up. Gastrointest Endosc 1995;42:13-18.
6. Sanes S, Maccallum JD. Primary carcinoma of the liver: cholangioma in hepatolithiasis. Am J Pathol 1942;18:675-687.
7. Chijiwa K, Ichimiy H, Kuroki S, Koga A, Nakayama F. Late development of cholangiocarcinoma after the treatment of hepatolithiasis. Surg Gynecol Obstet 1993;177:279-282.
8. Sheen-Chen SM, Chou FF, Eng HL. Intrahepatic cholangiocarcinoma in hepatolithiasis: a frequently overlooked disease. J Surg Oncol 1991;47:131-135.
9. Tsunoda T, Furui J, Yamada M, et al. Caroli’s disease associated with hepatolithiasis: a case report and review of the Japanese literature. Gastroenterol Jpn 1991;26:74-79.
10. Su CH, Shyr YM, Lui WY, P’eng FK. Hepatolithiasis associated with cholangiocarcinoma. Br J Surg 1997;84:969-973.
11. Falchuk KR, Lesser PB, Galdabini JJ, Isselbacher KJ. Cholangiocarcinoma as related to chronic intrahepatic cholangitis and hepatolithiasis. Case report and review of the literature. Am J Gastroenterol 1976;66:57-61.
12. Nakanuma Y, Terada T, Tanaka Y, Ohita G. Are hepatolithiasis and cholangiocarcinoma aetiologically related? A morphological study of 12 cases of hepatolithiasis associated with cholangiocarcinoma. Virchows Arch A Pathol Anat Histopathol 1985;406:45-58.
13. Ohita T, Nagakawa T, Konishi I, et al. Clinical experience of intrahepatic cholangiocarcinoma associated with hepatolithiasis. Jpn J Surg 1988;18:47-53.
14. Sato M, Watanabe Y, Horiuchi S, et al. Long-term results of hepatic resection for hepatolithiasis. HPB Surg 1995;9:37-41.
15. Hung CJ, Lin PW. Role of right hepatic lobectomy in the treatment of isolated right-sided hepatolithiasis. Surgery 1997;121:130-134.
16. Otani K, Shimizu S, Chijiwa K, et al. Comparison of treatments for hepatolithiasis: hepatic resection versus choangioscopic lithotomy. J Am Coll Surg 1999;189:177-182.
17. Abdalla EK, Forsmark CE, Lauwers GY, Vauthey JN. Monolobar Caroli’s disease and cholangiocarcinoma. HPB Surg 1999;11:271-276.
18. Akisawa N, Maeda T, Tsuda K, et al. Primary biliary cirrhosis asso-
associated with cholangiocarcinoma. Dig Dis Sci 1998;43:2138-2142.
19. Choi BI, Han JK, Hong ST, Lee KH. Clonorchiasis and cholangiocarcinoma: etiologic relationship and imaging diagnosis. Clin Microbiol Rev 2004;17:540-552.
20. Kim YT, Byun JS, Kim J, et al. Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis. Hepatogastroenterology 2003;50:8-12.
21. Wee A, Ludwig J, Coffey RJ Jr, LaRusso NF, Wiesner RH. Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol 1985;16:719-726.
22. Suh KS, Roh HR, Koh YT, Lee KU, Park YH, Kim SW. Clinico-pathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology 2000;31:12-17.
23. Kim HJ, Yun SS, Jung KH, Kwun WH, Choi JH. Intrahepatic cholangiocarcinoma in Korea. J Hepatobiliary Pancreat Surg 1999;6:142-148.
24. Park HS, Lee JM, Kim SH, et al. CT Differentiation of cholangiocarcinoma from peri ductal fibrosis in patients with hepatolithiasis. AJR Am J Roentgenol 2006;187:445-453.
25. Cheung MT, Kwok PC. Liver resection for intrahepatic stones. Arch Surg 2005;140:993-997.
26. Cheon YK, Cho YD, Moon JH, Lee JS, Shim CS. Evaluation of long-term results and recurrent factors after operative and nonoperative treatment for hepatolithiasis. Surgery 2009;146:843-853.